Frequency Therapeutics
300 Technology Square, 8th Floor
Cambridge
Massachusetts
02139
United States
Website: http://www.frequencytx.com/
Email: frequencytx@macbiocom.com
About Frequency Therapeutics
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.YEAR FOUNDED:
2015
LEADERSHIP:
Co-founder and CEO: David Luccino
Co-founder and CSO: Chris Loose, Ph.D.
Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.
COO: Michael Jirousek, Ph.D.
CMO: Peter C. Weber, M.D., M.B.A.
Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.
TECHNOLOGY:
Please click here for Frequency Therapeutics' technology.
87 articles with Frequency Therapeutics
-
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
3/10/2023
Frequency Therapeutics, Inc. today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
-
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
2/27/2023
Frequency Therapeutics, Inc. today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences.
-
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
2/13/2023
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).
-
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
12/19/2022
Frequency Therapeutics, Inc. today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program.
-
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
12/15/2022
Frequency Therapeutics, Inc. today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company’s second hearing restoration candidate for sensorineural hearing loss (SNHL).
-
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
11/17/2022
Frequency Therapeutics, Inc. today announced that it will host a virtual investor event on December 13, 2022.
-
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
11/8/2022
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.
-
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
10/12/2022
Frequency Therapeutics, Inc. today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL).
-
Frequency Therapeutics to Participate in September Investor and Medical Conferences
8/30/2022
Frequency Therapeutics, Inc. today announced that members of its management team will participate in investor and medical conferences later this month.
-
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
8/9/2022
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.
-
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
5/4/2022
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.
-
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
4/22/2022
Frequency Therapeutics, Inc. today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.
-
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Frequency Therapeutics, Inc. today announced business updates and financial results for the fourth quarter and full year ended December 31, 2021.
-
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference.
-
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
11/15/2021
Frequency Therapeutics, Inc. today announced business updates and financial results for the third quarter ended September 30, 2021.
-
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
11/9/2021
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322
-
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
10/27/2021
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
10/21/2021
Frequency Therapeutics, Inc. today announced that the first subject has been dosed in a new FX-322 Phase 2b study (FX-322-208) being conducted in a refined population of individuals with SNHL.
-
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
9/22/2021
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points